Immunotherapy may stall rare adrenal cancer progression
NCT ID NCT07085572
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 23 times
Summary
This study tests whether the immunotherapy drug cemiplimab can delay or prevent cancer growth in people with advanced adrenocortical cancer whose disease was controlled by initial chemotherapy. About 31 adults whose cancer did not worsen after 4-6 cycles of first-line treatment will receive cemiplimab as maintenance therapy. The main goal is to see how many remain progression-free at 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
S.C. Oncologia - ASST Spedali Civili di Brescia
RECRUITINGBrescia, Brescia, 25123, Italy
Conditions
Explore the condition pages connected to this study.